Hal V. Barron

Last updated
Hal V. Barron
Alma mater Washington University in St. Louis,
Yale University, University of California, San Francisco
Scientific career
Fields Physician
Institutions University of California, San Francisco (UCSF), Calico (company), Genentech, Hoffmann-La Roche

Hal V. Barron (born 1962) is an American clinician-scientist and drug developer who served as president of research and development at GlaxoSmithKline from March 2018 [1] until 2022, when he resigned in order to join the cellular reprogramming venture Altos Labs in August of that year. [2] [3] [4] Prior to this he served as president of research and development at Calico. [5] He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche. [6]

Contents

Career

Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. [7] In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.

On September 18, 2013, Barron was named President of Research and Development of Calico, a new company focusing on the biology of aging. [8] The company was created and funded by Google. [9]

On November 8, 2017, Barron became the new CSO and research chief at GlaxoSmithKline amid a shake-up from its new CEO Emma Walmsley. Barron was quoted: "GSK is a company with a rich history of innovation, with many talented scientists who care deeply about translating great science into therapies that make a meaningful difference for patients. I believe there is a significant opportunity to accelerate this effort and am looking forward to joining Emma and the team on this mission.” [10]

In April 2019, it was publicly reported that Barron spent excessively on travel expenses during the previous year. The total expenses exceeded $807,000 (£620,000). Shareholders, investors, and rank-and-file employees have all expressed concern tilting towards outrage that he has been allow to spend so freely while others are constrained and employee layoffs continue. [11]

In January 2022, it was announced that Barron will join Altos starting on 1 August 2022 at newly created biotech company Altos Labs, based in San Francisco. [4]

Barron's current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 80 papers in peer-reviewed scientific journals. [12] He was a member of the board of directors at Alexza Pharmaceuticals, and is a current member of the board of directors at Juno Therapeutics. [13]

Education

Barron received his medical degree from Yale School of Medicine and holds a Bachelor of Science degree in engineering physics from Washington University in St. Louis. He completed his training in medicine and cardiology at the University of California, San Francisco.

Related Research Articles

<span class="mw-page-title-main">GSK plc</span> UK healthcare company

GSK plc is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.

<span class="mw-page-title-main">Roche</span> Swiss multinational healthcare company

F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational holding healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX Swiss Exchange. The company headquarters are located in Basel. Roche is the fifth-largest pharmaceutical company in the world by revenue and the leading provider of cancer treatments globally. In 2023, the company’s seat in Forbes Global 2000 was 76.

<span class="mw-page-title-main">Human Genome Sciences</span> Former American pharmaceutical company, acquired by GlaxoSmithKline.

Human Genome Sciences (HGS) was a biopharmaceutical corporation founded in 1992 by Craig Venter, Alan Walton and Wally Steinberg. It uses the human DNA sequence to develop protein and antibody drugs. It had drugs under development to treat such diseases as hepatitis C, systemic lupus erythmatosis, anthrax, and cancer. It collaborated with other biotechnology and pharmaceutical companies for development partnerships and licensing.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 kms from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Arthur D. Levinson is an American businessman and is the chairman of Apple Inc. (2011–present) and chief executive officer (CEO) of Calico. He is the former CEO (1995–2009) and chairman (1999–2014) of Genentech.

<span class="mw-page-title-main">Andrew Witty</span> British business executive (born 1964)

Sir Andrew Philip Witty is a British business executive, who is the chief executive officer (CEO) of UnitedHealth Group. He was the CEO of GlaxoSmithKline between 2008 and 2017. He formerly held the role of chancellor of the University of Nottingham.

Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.

<span class="mw-page-title-main">Darapladib</span> Chemical compound

Darapladib is an inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA2) that is in development as a drug for treatment of atherosclerosis.

MorphoSys AG is a German biopharmaceutical company founded in 1992. The company is headquartered near Munich, Germany, and has a wholly owned subsidiary, MorphoSys US Inc., in Boston, Massachusetts, in the US. The company has various antibody, protein and peptide technologies that it uses to discover and develop both proprietary and partnered drug candidates. The company has more than 100 drugs in its wider pipeline that are being investigated for a variety of diseases. While many of these are being developed in partnership with pharma and biotech companies, MorphoSys also has a proprietary pipeline with a focus on cancer and autoimmune diseases.

Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Marc Tessier-Lavigne</span> Canadian neuroscientist (born 1959)

Marc Trevor Tessier-Lavigne is a Canadian-American neuroscientist who was the eleventh president of Stanford University.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

Calico Life Sciences LLC is an American biotechnology company with a focus on the biology of aging, attempting to devise interventions that may enable people to lead longer and healthier lives. It is a subsidiary of Alphabet Inc.

<span class="mw-page-title-main">Robert Califf</span> American cardiologist (born 1951)

Robert McKinnon Califf is an American cardiologist who currently serves as the 25th Commissioner of the Food and Drug Administration.

<span class="mw-page-title-main">Emma Walmsley</span> British businesswoman

Dame Emma Natasha Walmsley is the chief executive officer (CEO) of GlaxoSmithKline. She succeeded Sir Andrew Witty, who retired in March 2017. Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. She grew up in Barrow-in-Furness, Cumbria, England.

Galvani Bioelectronics is a Stevenage, United Kingdom-based bioelectronics R&D company.

Paul-Peter Tak M.D. PhD FMedSci is an immunologist and academic specialising in the fields of internal medicine, rheumatology and immunology. Tak has been the President & CEO of Candel Therapeutics since September 2020.

<span class="mw-page-title-main">Moncef Slaoui</span> Moroccan-American-Belgian doctor and researcher

Moncef Mohamed Slaoui is a Moroccan-born Belgian-American researcher who served as the head of Operation Warp Speed (OPWASP) under President Donald Trump from 2020 to 2021.

References

  1. ↑ "Wires". Cnbc.com. Retrieved 13 February 2019.
  2. ↑ Carroll, John (January 19, 2022). "What kind of biotech startup wins a $3B syndicate, woos a gallery of marquee scientists and recruits GSK's Hal Barron as CEO in a stunner? Let Rick Klausner explain". Endpoints News . Retrieved 19 June 2022.
  3. ↑ "Altos Labs: Executive Leadership". Altos Labs . Retrieved 19 June 2022.
  4. 1 2 Kollewe, Julia (19 January 2022). "GSK's top scientist jumps ship in new blow for pharmaceutical firm". The Guardian . Retrieved June 19, 2022.
  5. ↑ "I'm excited to announce Calico, a new company that will focus on health and w..." Plus.google.com. Retrieved 13 February 2019.
  6. ↑ "Roche - Roche and Genentech announce organizational and leadership decisions". Archived from the original on 2009-04-19. Retrieved 2014-06-04.
  7. ↑ "Genentech: Press Releases - Tuesday, May 14, 2002". Gene.com. Retrieved 13 February 2019.
  8. ↑ "Home". calicolabs.com.
  9. ↑ "Google announces Calico, a new company focused on health and well-being – News announcements – News from Google – Google". Googlepress.blogspot.com. Retrieved 13 February 2019.
  10. ↑ "Roche, Calico vet Hal Barron takes GSK R&D hot seat, as Vallance out - FierceBiotech". Fiercebiotech.com. 8 November 2017. Retrieved 13 February 2019.
  11. ↑ Mkandawire, Vinjeru (2019-04-14). "GSK's jet-set scientist racks up travel bill worth nearly $800k". The Telegraph. ISSN   0307-1235 . Retrieved 2022-10-19.
  12. ↑ "Pubmed search" . Retrieved 15 April 2019.
  13. ↑ "Hal Barron – Juno Therapeutics". Junotherapeutics.com. Retrieved 13 February 2019.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.